Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Interview with the Innovators
Ovarian Cancer Series
2022
2021
2020
Relapsed/Refractory Follicular Lymphoma
PET/CT Imaging in Prostate Cancer Patients
NTRK
Gene Fusions
Ovarian Cancer Series
Ovarian Cancer Series
Ovarian Cancer Series
An Expert Perspective on the Current and Future of Maintenance Therapy in Ovarian Cancer
By
Amina Ahmed, MD
;
Paula Anastasia, RN, MN, AOCN
;
Ali McBride, PharmD, MS
Interview with the Innovators
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, provide their support for the use of PARP inhibitors as maintenance therapy in ovarian cancer, and that the optimization of this therapy requires further research to discover the best therapeutic combinations that will be personalized based on patient characteristics.
Read More ›
Ovarian Cancer Series
Immunotherapy in Combination with PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
By
Amina Ahmed, MD
;
Paula Anastasia, RN, MN, AOCN
;
Ali McBride, PharmD, MS
Interview with the Innovators
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, consider the current and future use of immunotherapy, either alone or in combination with other agents such as PARP inhibitors, as first-line maintenance therapy in ovarian cancer.
Read More ›
Ovarian Cancer Series
Adverse Events and Improvements in Quality of Life Associated with First-Line Maintenance Therapy in Ovarian Cancer
By
Paula Anastasia, RN, MN, AOCN
;
Ali McBride, PharmD, MS
Interview with the Innovators
Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, describe the impact that first-line maintenance therapy has on quality of life in patients with ovarian cancer despite adverse events associated with the treatment, and that frequent communication with the healthcare team during maintenance therapy is critical.
Read More ›
Ovarian Cancer Series
Management of Adverse Events Associated with PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
By
Paula Anastasia, RN, MN, AOCN
;
Ali McBride, PharmD, MS
Interview with the Innovators
Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, provide their insights on the occurrence and management of the most common hematologic and nonhematologic adverse events associated with several PARP inhibitors that are used as maintenance therapy in ovarian cancer.
Read More ›
Ovarian Cancer Series
Combination Therapy as Maintenance in Ovarian Cancer
By
Amina Ahmed, MD
;
Paula Anastasia, RN, MN, AOCN
;
Ali McBride, PharmD, MS
Interview with the Innovators
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, discuss the benefits and risks of using combination therapy with a PARP inhibitor and bevacizumab as first-line maintenance therapy in ovarian cancer.
Read More ›
Ovarian Cancer Series
Clinical Data on First-Line Maintenance Therapy in Ovarian Cancer
By
Amina Ahmed, MD
;
Paula Anastasia, RN, MN, AOCN
;
Ali McBride, PharmD, MS
Interview with the Innovators
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN and Ali McBride, PharmD, critically review the clinical trial data supporting the use of PARP inhibitors and bevacizumab as first-line maintenance therapy in ovarian cancer.
Read More ›
Ovarian Cancer Series
Choosing Among PARP Inhibitors as Maintenance Therapy in Ovarian Cancer
By
Amina Ahmed, MD
;
Paula Anastasia, RN, MN, AOCN
;
Ali McBride, PharmD, MS
Interview with the Innovators
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN and Ali McBride, PharmD, describe their experiences in the use of niraparib, olaparib and nucaparib as first-line maintenance therapy in Ovarian Cancer.
Read More ›
Ovarian Cancer Series
Choosing Maintenance Therapy in Ovarian Cancer
By
Amina Ahmed, MD
;
Paula Anastasia, RN, MN, AOCN
;
Ali McBride, PharmD, MS
Interview with the Innovators
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, discuss the relative benefits and risks of maintenance therapy in ovarian cancer with bevacizumab versus a PARP inhibitor.
Read More ›
Ovarian Cancer Series
A Review of Clinical Trials Suggesting the Use of PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
By
Amina Ahmed, MD
;
Paula Anastasia, RN, MN, AOCN
;
Ali McBride, PharmD, MS
Interview with the Innovators
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, deliberate on results from recent clinical trials showing the improvement in progression-free survival after first-line maintenance therapy with PARP inhibitors in patients with ovarian cancer, regardless of HRD status. The experts consider the impact of these data on providing improved treatment options for these patients.
Read More ›
Ovarian Cancer Series
Changes in HRD “Fingerprints” in Patients with Ovarian Cancer and Their Impact on Clinical Outcomes
By
Amina Ahmed, MD
;
Paula Anastasia, RN, MN, AOCN
Interview with the Innovators
Amina Ahmed, MD, and Paula Anastasia, RN, MN, AOCN, debate the need for rebiopsy and retesting of molecular biomarkers in patients with HRD-discordant responses. The experts agree that reliability of the HRD “fingerprint” is dependent on the validity of the HRD test used as well as the ability to interpret results from these tests.
Read More ›
Page 1 of 2
1
2
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Molecular Characteristics Increasingly Define Adult Gliomas
By
William King
2.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
By
William King
3.
Optimal Systemic Therapy for Renal Cell Carcinoma Is Still Evolving
By
William King
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes